---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Prevalence"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Prevalence. Topics: Company estimate: 80 million US adults aged 30 to 69 and one billion people worldwide (Clarivate study commissioned by Apnimed); Company estimate: newly diagnosed, diagnosed and active in care, and diagnosed but untreated US adults (claims databases and a survey); Company estimate: new diagnosis rate and initial target population, September 2026 corporate presentation; Company estimate: share of middle-aged and older adults with OSA who are not obese (third-party study supported by Apnimed); 14 further topics. 18 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/prevalence"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Obstructive sleep apnea

<a id="topic-2.2.1.2.2-1"></a>

### Company estimate: 80 million US adults aged 30 to 69 and one billion people worldwide (Clarivate study commissioned by Apnimed)

> “OSA is a highly prevalent condition, estimated to be affecting approximately 80 million people in the United States between the ages of 30-69, according to a study we commissioned from Clarivate Plc. (Clarivate).”
> “The total addressable market for Oxnimbi includes the estimated 80 million adults in the United States and approximately one billion people worldwide with OSA, encompassing both diagnosed and undiagnosed individuals according to a study we commissioned from Clarivate and the World Health Organization (the WHO), respectively.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.1.2.2-2"></a>

### Company estimate: newly diagnosed, diagnosed and active in care, and diagnosed but untreated US adults (claims databases and a survey)

> “Each year, approximately three million people are newly diagnosed according to Komodo Health, Inc.’s (Komodo) medical claims database.”
> “Our analysis of U.S. IQVIA Holdings Inc. (NYSE: IQV) (IQVIA) claims data indicates that over a five-year period from 2019 to 2024, approximately 23 million unique patients with a diagnosis of OSA were active within the healthcare system.”
> “Research from the National Sleep Foundation indicates that approximately 10.5 million people in the United States are diagnosed with OSA but are not currently receiving treatment.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.1.2.2-3"></a>

### Company estimate: new diagnosis rate and initial target population, September 2026 corporate presentation

> “New diagnosis rate >3M/year”
> “Initial target is ~10.5M diagnosed not on PAP”

Source: [Apnimed presentation (2026)](https://ir.apnimed.com/static-files/69419ee6-af17-4ba9-9b99-4fccd6e88177)

<a id="topic-2.2.1.2.2-4"></a>

### Company estimate: share of middle-aged and older adults with OSA who are not obese (third-party study supported by Apnimed)

> “A third party study, supported by certain company personnel and a grant from us in the community setting, estimates that more than 60% of middle-aged and older adults living with OSA are not obese.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-2.2.1.2.2-5"></a>

### US prevalence in 2024, AHI4 of 5 or more, adults aged 20 years and older (systematic review and obesity-adjusted projection by Clarivate and Apnimed authors)

> “A literature-based systematic review was conducted to identify studies of OSA prevalence in adults using the AHI4 criteria (all apneas plus hypopneas associated with ≥4% oxygen desaturation).”
> “OSA was defined as having an AHI4 ≥ 5 events/hr.”
> “A total of 83.7 million adults (aged 20 years and older) were estimated to be living with OSA in the US in 2024, of whom 49,459,041 (59%) were males and 34,257,378 (41%) females.”
> “This translates to 32.4% overall prevalence in the US among adults aged 20 years and older, with 39.1% among males and 26.0% in females, adjusting for obesity.”
> “The distribution of OSA severity was estimated to be 52% mild, 30% moderate, and 18% severe.”
> “I.S. and A.V.D. are employees of Clarivate Analytics. K.S.Y., J.C., and J.Y. are employees of Apnimed, Inc.”

Source: [Sönmez et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40957495/)

<a id="topic-2.2.1.2.2-6"></a>

### Self-reported diagnosed but untreated sleep apnea, US adults aged 18 to 90 (National Sleep Foundation survey with support from Inspire Medical Systems)

> “A Report from National Sleep Foundation, with Support from Inspire Medical Systems, Inc.”
> “The final sample was comprised of 1,015 American adults ages 18-90 years old (M = 48, SD = 18.21) who were representative of the US adult population (i.e., 61% White, 12% Black, and 18% Hispanic; 51% female).”
> “Of the 19% of adults who have had some form of diagnostic workup, 13% reported being diagnosed; however, 4% of those diagnosed with sleep apnea say they are not currently being treated.”
> “Stated differently, approximately 31%, or over 10.5 million adults, diagnosed with sleep apnea are not currently receiving needed treatment.”
> “Eleven percent of those who have never been tested or diagnosed have a suspicion that they likely have sleep apnea—this equates to just over 29 million people who think they might have sleep apnea.”

Source: [National Sleep Foundation (2025)](https://www.thensf.org/wp-content/uploads/2025/03/NSF-Inpsire-Report_2025-1.pdf)

<a id="topic-2.2.1.2.2-7"></a>

### US prevalence in 2007 to 2010, AHI of 5 or more and 15 or more with 4% desaturation hypopnea rule, adults aged 30 to 70 (Wisconsin Sleep Cohort extrapolated to NHANES body mass index distributions)

> “A discernible reduction in the sum of thoracic plus abdomen respiratory inductance plethysmography amplitude associated with a 4% or more reduction in oxyhemoglobin saturation defined a hypopnea event.”
> “The current prevalence estimates of moderate to severe sleep-disordered breathing (apnea-hypopnea index, measured as events/hour, ≥15) are 10% (95% confidence interval (CI): 7, 12) among 30–49-year-old men; 17% (95% CI: 15, 21) among 50–70-year-old men; 3% (95% CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old women.”
> “These estimated prevalence rates represent substantial increases over the last 2 decades (relative increases of between 14% and 55% depending on the subgroup).”
> “Summing over age × sex × BMI strata, we estimated the overall prevalence of mild to severe SDB (AHI ≥5) to be 26% (95% confidence interval: 24, 28) among person 30–70 years of age for the recent time period (2007–2010).”
> “Similarly, the estimated overall prevalence of moderate to worse SDB (AHI ≥15) was 10% (95% confidence interval: 8, 11).”
> “We also estimate that 14% of men and 5% of women have an AHI ≥5 plus symptoms of daytime sleepiness.”

Source: [Peppard et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3639722/)

<a id="topic-2.2.1.2.2-8"></a>

### Global prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (ResMed-funded)

> “A conversion algorithm was created for studies that did not use the American Academy of Sleep Medicine (AASM) 2012 scoring criteria to identify obstructive sleep apnoea, allowing determination of an equivalent apnoea-hypopnoea index (AHI) for publications that used different criteria.”
> “Using AASM 2012 diagnostic criteria and AHI threshold values of five or more events per h and 15 or more events per h, we estimated that 936 million (95% CI 903–970) adults aged 30–69 years (men and women) have mild to severe obstructive sleep apnoea and 425 million (399–450) adults aged 30–69 years have moderate to severe obstructive sleep apnoea globally.”
> “The number of affected individuals was highest in China, followed by the USA, Brazil, and India.”
> “AVB, KV, and CMN are employees of ResMed.”
> “Funding ResMed.”

Source: [Benjafield et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007763/)

<a id="topic-2.2.1.2.2-9"></a>

### US prevalence, AHI of 5 or more and 15 or more with AASM 2012 criteria, adults aged 30 to 69 (country table of the global estimate)

| Measure | United States |
| --- | --- |
| Population aged 30–69 years | “163 246 772” |
| AHI ≥5 events per h, n (%) | “54 131 654 (33·2%)” |
| AHI ≥15 events per h, n (%) | “23 678 109 (14·5%)” |

Source: [Benjafield et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7007763/)

<a id="topic-2.2.1.2.2-10"></a>

### US prevalence projected from 2020 to 2050, AHI of 5 or more, adults aged 30 to 69, hypopnea scoring rule not stated (ResMed-funded simulation model)

> “This study was funded by Resmed.”
> “Obstructive sleep apnoea diagnosis was based age, sex, BMI, and AHI, a metric reflecting the number of apnoea and hypopnoea events per hour of sleep,22 with individuals considered to have obstructive sleep apnoea if their AHI was 5/h or higher.”
> “By 2050, the prevalence of obstructive sleep apnoea (apnoea–hypopnoea index ≥5/h) is expected to show a relative increase of 34·7%, from 34·3% (95% uncertainty interval [UI] 34·0–34·4) to 46·2% (46·0–46·4), resulting in 76·6 million cases.”
> “Males are projected to show a more moderate relative increase of 19·3%, from 45·6% (45·4–46·0) to 54·4% (54·2–54·7), reaching 45·9 million cases.”
> “Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a disproportionate growth among females compared with males.”

Source: [Boers et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12674968/)

<a id="topic-2.2.1.2.2-11"></a>

### Prevalence of AHI of 15 or more with AASM 2012 hypopnea rule, adults aged 40 to 85 in Lausanne, Switzerland (HypnoLaus)

> “We used the 2012 criteria for our analysis (because they are the most recent and currently recommended criteria) and reported the average number of apnoea and hypopnoea events per h of sleep (the apnoea-hypopnoea index).”
> “1024 (48%) participants were men, with a median age of 57 years (IQR 49–68, range 40–85) and mean body-mass index (BMI) of 25·6 kg/m2 (SD 4·1).”
> “The prevalence of moderate-to-severe sleep-disordered breathing (≥15 events per h) was 23·4% (95% CI 20·9–26·0) in women and 49·7% (46·6–52·8) in men.”

Source: [Heinzer et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4404207/)

<a id="topic-2.2.1.2.2-12"></a>

### Prevalence of an apnea-hypopnea score of 5 or more, employed Wisconsin adults aged 30 to 60 (Wisconsin Sleep Cohort, polysomnography)

> “A random sample of 602 employed men and women 30 to 60 years old were studied by overnight polysomnography to determine the frequency of episodes of apnea and hypopnea per hour of sleep (the apnea-hypopnea score).”
> “The estimated prevalence of sleep-disordered breathing, defined as an apnea-hypopnea score of 5 or higher, was 9 percent for women and 24 percent for men.”
> “We estimated that 2 percent of women and 4 percent of men in the middle-aged work force meet the minimal diagnostic criteria for the sleep apnea syndrome (an apnea-hypopnea score of 5 or higher and daytime hypersomnolence).”

Source: [Young et al. (1993)](https://pubmed.ncbi.nlm.nih.gov/8464434/)

<a id="topic-2.2.1.2.2-13"></a>

### Range of general-population prevalence across 24 studies, AHI of 5 or more and 15 or more (systematic review)

> “Twenty-four studies out of 3807 found by systematically searching PubMed and Embase databases were included in this review.”
> “At ≥5 events/h apnea-hypopnea index (AHI), the overall population prevalence ranged from 9% to 38% and was higher in men.”
> “It increased with increasing age and, in some elderly groups, was as high as 90% in men and 78% in women.”
> “At ≥15 events/h AHI, the prevalence in the general adult population ranged from 6% to 17%, being as high as 49% in the advanced ages.”

Source: [Senaratna et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27568340/)

<a id="topic-2.2.1.2.2-14"></a>

### Prevalence in clinical populations: bariatric surgery candidates and people with stroke or transient ischemic attack

> “In some populations, the prevalence of OSA is substantially higher than this estimate, for example, in patients being evaluated for bariatric surgery (estimated range of 70% to 80%)11 or in patients who have had a transient ischemic attack or stroke (estimated range of 60% to 70%).”

Source: [Kapur et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5337595/)

<a id="topic-2.2.1.2.2-15"></a>

### Undiagnosed share of moderate to severe sleep apnea syndrome, employed adults in Wisconsin

> “In this population, without obvious barriers to health care for sleep disorders, we estimate that 93% of women and 82% of men with moderate to severe SAS have not been clinically diagnosed.”

Source: [Young et al. (1997)](https://pubmed.ncbi.nlm.nih.gov/9406321/)

<a id="topic-2.2.1.2.2-16"></a>

### Diagnosed and undiagnosed US adults, AHI over 5 (Frost & Sullivan report commissioned by the AASM)

> “Frost & Sullivan was commissioned by the AASM to investigate the dynamics of sleep apnea diagnosis and treatment, and its impact on healthcare and workplace economics in the United States.”
> “Prevalence OSA (AHI>5)”
> “Frost & Sullivan estimates the prevalence of OSA to be 12% or 29.4 million of the U.S. adult population with nearly 80% of the population undiagnosed.”
> “Frost & Sullivan estimates that out of the 29.4 million U.S. adults with OSA, only 20% or 5.9 million individuals have been diagnosed.”

Source: [Frost & Sullivan (2016)](https://aasm.org/resources/pdf/sleep-apnea-economic-crisis.pdf)

<a id="topic-2.2.1.2.2-17"></a>

### Diagnosed prevalence in US insured adults and children with claims activity, 2013 to 2016 (nationwide claims, Jazz Pharmaceuticals-funded)

> “Nationwide medical/prescription claims (Symphony Health) were analyzed to estimate the annual prevalence per 100,000 persons of narcolepsy and other sleep disorders (obstructive sleep apnea, idiopathic hypersomnia, rapid eye movement sleep behavior disorder, periodic limb movement disorder) and the frequency of diagnostic sleep testing.”
> “Obstructive sleep apnea prevalence increased 41% over the study period from 2,429 to 3,420 per 100,000.”
> “This study was funded by Jazz Pharmaceuticals.”

Source: [Acquavella et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7446073/)

<a id="topic-2.2.1.2.2-18"></a>

### Documented sleep-related breathing disorders in Veterans Affairs outpatients, 2018

> “Similarly, a review of VA medical records revealed an increase in documented diagnoses of both OSA and insomnia, with 22% of outpatients diagnosed with sleep-related breathing disorders and 11.8% diagnosed with insomnia in 2018.”

Source: [VA/DoD insomnia and obstructive sleep apnea guideline (2025)](https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/CD/insomnia/I-OSA-CPG_2025-Guideline_final_20250915.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
